Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified. > Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes: > Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale > Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale
Duty Rate (from China)
Products classified under Tariff item 3002.13.00
Adalimumab High-Concentration Solution
Adalimumab high-concentration solution is a fully human monoclonal antibody against TNF-alpha, used for autoimmune diseases like psoriasis. As an aqueous solution of an unmixed product, it is treated as unmixed under chapter note 3(a)(1) and qualifies for tariff item 3002.13.00.
Adalimumab Monoclonal Antibody
Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) and is used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease. This product is imported in bulk, unmixed form, not put up in measured doses or retail packaging, which qualifies it under tariff item 3002.13.00 as an immunological product.
Atezolizumab Monoclonal Antibody
Atezolizumab is a humanized IgG1 monoclonal antibody that blocks PD-L1 and is used in the treatment of bladder cancer and other malignancies. Imported as an unmixed bulk substance without measured doses or retail packaging, it falls under tariff item 3002.13.00 as an immunological product obtained by biotechnological processes.
Bevacizumab Monoclonal Antibody
Bevacizumab is a humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) and is used to treat colorectal and lung cancers. This bulk, unmixed product is not in measured doses or retail packaging, making it classifiable under tariff item 3002.13.00 as an immunological product.
Blinatumomab Monoclonal Antibody
Blinatumomab is a bispecific T-cell engager (BiTE) monoclonal antibody used for the treatment of acute lymphoblastic leukemia. As an unmixed biotechnological product not put up in measured doses or retail sale forms, it is classified under tariff item 3002.13.00.
Bulk Colony Stimulating Factor G-CSF
Bulk Colony Stimulating Factor G-CSF (Filgrastim) is a recombinant protein that stimulates neutrophil production, primarily used post-chemotherapy. It is an unmixed immunological product, not put up in measured doses or for retail sale, and is classified under tariff item 3002.13.00 as per Chapter 30 Note 2, which covers colony stimulating factors.
Bulk Filgrastim
Bulk Filgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) analog that stimulates the production of neutrophils. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as a hematopoietin directly involved in the regulation of immunological processes.
Bulk Granulocyte Colony Stimulating Factor (G-CSF)
Bulk Granulocyte Colony Stimulating Factor (G-CSF) is a recombinant protein that promotes the production of neutrophils, classified as a hematopoietin under the chapter notes. It is supplied unmixed, without measured doses or retail packaging, and is used as an active pharmaceutical ingredient. This product falls under tariff item 3002.13.00 as an unmixed immunological product.
Bulk Infliximab
Bulk Infliximab is a chimeric monoclonal antibody against tumor necrosis factor (TNF), used in the treatment of autoimmune diseases. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Bulk Interferon Alpha-2a
Bulk Interferon Alpha-2a is a recombinant cytokine protein used for antiviral and anticancer treatment. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as an interferon directly involved in the regulation of immunological processes.
Bulk Pembrolizumab
Bulk Pembrolizumab is a PD-1 inhibitor monoclonal antibody used in immuno-oncology. It is an unmixed immunological product obtained by biotechnological processes, not in measured doses or retail packs, and is classified under 3002.13.00 per Chapter 30 Note 2.
Bulk Rituximab Immunological Product
Bulk Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells, used in lymphoma and autoimmune disease therapy. It is an unmixed immunological product produced via biotechnological processes, not for retail sale, and is classified under 3002.13.00.
Bulk Rituximab Monoclonal Antibody
Bulk Rituximab Monoclonal Antibody is a chimeric antibody targeting CD20 on B-cells, used for lymphoma and autoimmune disease treatment. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Bulk Trastuzumab Emtansine Conjugate
Bulk Trastuzumab Emtansine is an antibody-drug conjugate (ADC) combining a monoclonal antibody with a chemotherapy agent for HER2-positive breast cancer. It is an unmixed immunological product under 3002.13.00, as it is not put up in measured doses or retail packs.
Cetuximab Bulk Active
Cetuximab Bulk Active is a monoclonal antibody targeting EGFR for colorectal cancer treatment. It is an unmixed immunological product produced biotechnologically, not in measured doses or retail packaging, and is classified under 3002.13.00.
Cetuximab Monoclonal Antibody
Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is used in colorectal and head-and-neck cancer therapy. Imported in bulk, unmixed form without retail packaging, it falls under tariff item 3002.13.00 as an immunological product.
Daratumumab Monoclonal Antibody
Daratumumab is a human IgG1k monoclonal antibody targeting CD38, used for the treatment of multiple myeloma. As an unmixed bulk product not in measured doses or retail packaging, it is classifiable under tariff item 3002.13.00.
Denosumab Drug Substance
Denosumab Drug Substance is a RANKL inhibitor monoclonal antibody for osteoporosis and cancer bone metastases. It is an unmixed immunological product, not in measured doses or retail packs, and is classified under 3002.13.00.
Denosumab Monoclonal Antibody
Denosumab is a fully human monoclonal antibody that inhibits RANKL and is used to treat osteoporosis and bone metastases. This bulk, unmixed product is not put up in measured doses or retail packaging, qualifying it for tariff item 3002.13.00.
Dupilumab Drug Substance
Dupilumab Drug Substance is an IL-4/IL-13 inhibitor monoclonal antibody for atopic dermatitis and asthma. It is an unmixed biotechnological immunological product, not in measured doses or retail packaging, and is classified under 3002.13.00.
Infliximab Monoclonal Antibody
Infliximab is a chimeric monoclonal antibody that neutralizes TNF-alpha and is used to treat Crohn's disease, psoriasis, and other autoimmune conditions. Imported as an unmixed bulk product without retail packaging, it is classified under tariff item 3002.13.00.
Interferon Beta-1a Bulk Preparation
Interferon Beta-1a Bulk Preparation is a recombinant cytokine for multiple sclerosis treatment, modulating immune response. It is an unmixed, biotechnological immunological product not in measured doses, and is classified under 3002.13.00.
Nivolumab Drug Substance
Nivolumab Drug Substance is a bulk PD-1 blocking antibody for melanoma and lung cancer therapy. It is an unmixed immunological product obtained via biotechnological processes, not in measured doses or retail packs, and is classified under 3002.13.00.
Nivolumab Monoclonal Antibody
Nivolumab is a human monoclonal antibody that inhibits PD-1 and is used in cancer immunotherapy for melanoma and lung cancer. This bulk, unmixed product is not in measured doses or retail packaging, making it classifiable under tariff item 3002.13.00.
Omalizumab Bulk
Omalizumab Bulk is an anti-IgE monoclonal antibody for severe asthma. It is an unmixed immunological product regulating allergic immune responses, not in measured doses or retail packaging, and is classified under 3002.13.00.
Omalizumab Monoclonal Antibody
Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and is used to treat severe asthma. Imported as an unmixed bulk product without retail packaging, it falls under tariff item 3002.13.00 as an immunological product.
Pegfilgrastim Bulk
Pegfilgrastim Bulk is a pegylated form of G-CSF used to treat neutropenia. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as a colony-stimulating factor directly involved in the regulation of immunological processes.
Pembrolizumab Monoclonal Antibody
Pembrolizumab is a humanized IgG4 monoclonal antibody that blocks PD-1 and is used in immunotherapy for melanoma and lung cancer. This bulk, unmixed product is not put up in measured doses or retail packaging, qualifying it for tariff item 3002.13.00.
Ranibizumab Monoclonal Antibody
Ranibizumab is an affinity-matured humanized monoclonal antibody fragment used to treat wet age-related macular degeneration. As an unmixed bulk product not in measured doses or retail packaging, it is classified under tariff item 3002.13.00, with antibody fragments explicitly covered by chapter note 2.
Recombinant Erythropoietin (EPO)
Recombinant Erythropoietin (EPO) is a glycoprotein hormone that stimulates red blood cell production and has immunological regulatory roles. It is supplied unmixed, without measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as a growth factor directly involved in the regulation of immunological processes.
Recombinant Human Growth Factor (HGF)
Recombinant Human Growth Factor (HGF) is a protein that promotes cell growth and motility with immunological roles. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as a growth factor directly involved in the regulation of immunological processes.
Recombinant Interleukin-2 (IL-2)
Recombinant Interleukin-2 (IL-2) is a growth factor protein that stimulates immune cell proliferation, used in cancer immunotherapy. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as an interleukin directly involved in the regulation of immunological processes.
Rituximab Monoclonal Antibody
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used to treat non-Hodgkin lymphoma and rheumatoid arthritis. Imported in bulk, unmixed form without retail packaging, it falls under tariff item 3002.13.00.
Trastuzumab Monoclonal Antibody
Trastuzumab is a humanized monoclonal antibody that inhibits HER2 protein and is used in HER2-positive breast cancer therapy. As an unmixed bulk product not in measured doses or retail packaging, it is classifiable under tariff item 3002.13.00.
Unmixed Adalimumab Biosimilar
Unmixed Adalimumab Biosimilar is a TNF inhibitor monoclonal antibody used for treating rheumatoid arthritis. It is supplied unmixed, without measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Unmixed Cetuximab
Unmixed Cetuximab is an EGFR-targeting monoclonal antibody used for cancer therapy. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Unmixed Monoclonal Antibody Bevacizumab
Unmixed Monoclonal Antibody Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for cancer therapy. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Unmixed Omalizumab
Unmixed Omalizumab is an anti-IgE monoclonal antibody used for asthma treatment. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as an antibody directly involved in the regulation of immunological processes.
Unmixed Trastuzumab Emtansine Conjugate
Unmixed Trastuzumab Emtansine Conjugate is an antibody-drug conjugate targeting HER2 in breast cancer. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as an antibody conjugate directly involved in the regulation of immunological processes.
Unmixed Tumor Necrosis Factor Alpha (TNF-α)
Unmixed Tumor Necrosis Factor Alpha (TNF-α) is a cytokine involved in systemic inflammation and immune regulation, supplied in bulk for research and therapeutic development. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further manufacturing. It qualifies under tariff item 3002.13.00 as a tumor necrosis factor directly involved in the regulation of immunological processes.